News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,691 Results
Type
Article (39270)
Company Profile (282)
Press Release (650139)
Section
Business (203987)
Career Advice (2001)
Deals (35403)
Drug Delivery (90)
Drug Development (80899)
Employer Resources (168)
FDA (16120)
Job Trends (14819)
News (344821)
Policy (32473)
Tag
Academia (2530)
Alliances (49281)
Alzheimer's disease (1290)
Approvals (16082)
Artificial intelligence (161)
Bankruptcy (354)
Best Places to Work (11598)
Biotechnology (199)
Breast cancer (202)
Cancer (1499)
Cardiovascular disease (119)
Career advice (1667)
Cell therapy (308)
Clinical research (64920)
Collaboration (554)
Compensation (302)
COVID-19 (2547)
C-suite (129)
Data (1459)
Diabetes (185)
Diagnostics (6192)
Earnings (85016)
Employer resources (146)
Events (110327)
Executive appointments (462)
FDA (16880)
Funding (504)
Gene therapy (213)
GLP-1 (615)
Government (4336)
Healthcare (18739)
Infectious disease (2643)
Inflammatory bowel disease (112)
Interviews (309)
IPO (16378)
Job creations (3628)
Job search strategy (1420)
Layoffs (424)
Legal (7873)
Lung cancer (225)
Manufacturing (215)
Medical device (13227)
Medtech (13232)
Mergers & acquisitions (19265)
Metabolic disorders (487)
Neuroscience (1643)
NextGen: Class of 2025 (6506)
Non-profit (4471)
Northern California (1851)
Obesity (278)
Opinion (188)
Parkinson's disease (106)
Patents (133)
People (56609)
Phase I (20199)
Phase II (28589)
Phase III (21310)
Pipeline (606)
Postmarket research (2563)
Preclinical (8553)
Radiopharmaceuticals (239)
Rare diseases (280)
Real estate (5894)
Regulatory (21779)
Research institute (2312)
Resumes & cover letters (349)
Southern California (1596)
Startups (3567)
United States (16407)
Vaccines (571)
Weight loss (192)
Date
Today (83)
Last 7 days (806)
Last 30 days (2101)
Last 365 days (34973)
2025 (1403)
2024 (35269)
2023 (40089)
2022 (51179)
2021 (55714)
2020 (54093)
2019 (46548)
2018 (35022)
2017 (32114)
2016 (31483)
2015 (37554)
2014 (31321)
2013 (26347)
2012 (28575)
2011 (29270)
2010 (27337)
Location
Africa (713)
Arizona (202)
Asia (37419)
Australia (6104)
California (4183)
Canada (1531)
China (353)
Colorado (188)
Connecticut (199)
Europe (80063)
Florida (592)
Georgia (142)
Illinois (410)
Indiana (237)
Maryland (674)
Massachusetts (3240)
Michigan (180)
Minnesota (312)
New Jersey (1173)
New York (1189)
North Carolina (777)
Northern California (1851)
Ohio (151)
Pennsylvania (987)
South America (1093)
Southern California (1596)
Texas (603)
Utah (119)
Washington State (425)
689,691 Results for "daiichi sankyo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Press Releases
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
January 14, 2025
·
3 min read
Business
RevolKa Signed Master Service Agreement with Daiichi Sankyo
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform signed a master service agreement with Daiichi Sankyo Co., Ltd.
May 27, 2024
·
2 min read
Drug Development
AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study
AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.
May 28, 2024
·
2 min read
·
Tristan Manalac
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
November 13, 2024
·
10 min read
Business
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to Women Undergoing Breast Cancer Treatment
Mika Health, a global digital therapeutics developer specializing in meeting the needs of cancer patients, in collaboration with AstraZeneca and Daiichi Sankyo, announced at the HLTH Europe conference, a digital initiative to improve the experience of women receiving breast cancer treatments.
June 18, 2024
·
6 min read
Antibody-drug conjugate (ADC)
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
September 17, 2024
·
2 min read
·
Tristan Manalac
1 of 68,970
Next
